{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:35:07Z","timestamp":1775543707075,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>PMX53 and PMX205 are cyclic hexapeptide inhibitors of complement C5a receptors (C5aR1), that are widely used to study C5aR1 pathobiology in mouse models of disease. Despite their widespread use, limited information regarding their pharmacokinetics have been reported. Here, a bioanalytical method for the quantitative determination of PMX53 and PMX205 in plasma, brain and spinal cord of mice was developed using liquid chromatography-tandem mass spectrometry (LC-MS\/MS) techniques. The LC-MS\/MS method was validated in all three matrices according to regulatory guidelines and successfully applied to pharmacokinetic studies of PMX53 and PMX205 in C57BL\/6\u2009J mice following intravenous administration. The developed method was highly sensitive and sufficiently accurate with a lower limit of quantification within the range of 3\u20136\u2009ng\/ml in extracted plasma samples and 3\u20136\u2009ng\/g in processed tissue samples, which outperforms previously published LC-MS\/MS methods. The results thus support the suitability, reliability, reproducibility and sensitivity of this validated technique. This method can therefore be applied to perform a complete pre-clinical investigation of PMX53 and PMX205 pharmacokinetics in mice.<\/jats:p>","DOI":"10.1038\/s41598-018-26387-4","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T17:41:23Z","timestamp":1526665283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Development and validation of a LC-MS\/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice"],"prefix":"10.1038","volume":"8","author":[{"given":"Vinod","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-911X","authenticated-orcid":false,"given":"Trent M.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,25]]},"reference":[{"key":"26387_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molimm.2016.11.010","volume":"84","author":"OA Hawksworth","year":"2017","unstructured":"Hawksworth, O. A., Coulthard, L. G. & Woodruff, T. M. Complement in the fundamental processes of the cell. Mol Immunol 84, 17\u201325, https:\/\/doi.org\/10.1016\/j.molimm.2016.11.010 (2017).","journal-title":"Mol Immunol"},{"key":"26387_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.smim.2016.03.015","volume":"28","author":"FH Brennan","year":"2016","unstructured":"Brennan, F. H., Lee, J. D., Ruitenberg, M. J. & Woodruff, T. M. Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Semin Immunol 28, 292\u2013308, https:\/\/doi.org\/10.1016\/j.smim.2016.03.015 (2016).","journal-title":"Semin Immunol"},{"key":"26387_CR3","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1096\/fj.12-220509","volume":"27","author":"R Li","year":"2013","unstructured":"Li, R., Coulthard, L. G., Wu, M. C., Taylor, S. M. & Woodruff, T. M. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J 27, 855\u2013864, https:\/\/doi.org\/10.1096\/fj.12-220509 (2013).","journal-title":"FASEB J"},{"key":"26387_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bph.13730","volume":"174","author":"JD Lee","year":"2017","unstructured":"Lee, J. D. et al. Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. B. J. Pharmacol. 174, 689\u2013699 (2017).","journal-title":"B. J. Pharmacol."},{"key":"26387_CR5","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1096\/fj.05-5814com","volume":"20","author":"TM Woodruff","year":"2006","unstructured":"Woodruff, T. M. et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. Faseb J 20, 1407\u20131417, https:\/\/doi.org\/10.1096\/fj.05-5814com (2006).","journal-title":"Faseb J"},{"key":"26387_CR6","doi-asserted-by":"publisher","first-page":"6517","DOI":"10.1523\/JNEUROSCI.5218-14.2015","volume":"35","author":"FH Brennan","year":"2015","unstructured":"Brennan, F. H. et al. The complement receptor C5aR controls acute inflammation and astrogliosis following spinal cord injury. J. Neurosci. 35, 6517\u20136531 (2015).","journal-title":"J. Neurosci."},{"key":"26387_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nbd.2015.02.004","volume":"76","author":"MJ Benson","year":"2015","unstructured":"Benson, M. J. et al. A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models. Neurobiol. of disease 76, 87\u201397 (2015).","journal-title":"Neurobiol. of disease"},{"key":"26387_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.molimm.2017.05.015","volume":"89","author":"OA Hawksworth","year":"2017","unstructured":"Hawksworth, O. A., Li, X. X., Coulthard, L. G., Wolvetang, E. J. & Woodruff, T. M. New concepts on the therapeutic control of complement anaphylatoxin receptors. Mol Immunol 89, 36\u201343, https:\/\/doi.org\/10.1016\/j.molimm.2017.05.015 (2017).","journal-title":"Mol Immunol"},{"key":"26387_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrd4657","volume":"14","author":"BP Morgan","year":"2015","unstructured":"Morgan, B. P. & Harris, C. L. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 14, 857\u2013877, https:\/\/doi.org\/10.1038\/nrd4657 (2015).","journal-title":"Nat Rev Drug Discov"},{"key":"26387_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.bjp.0707332","volume":"152","author":"P Monk","year":"2007","unstructured":"Monk, P., Scola, A., Madala, P. & Fairlie, D. Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol. 152, 429\u2013448 (2007).","journal-title":"Br. J. Pharmacol."},{"key":"26387_CR11","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1021\/jm9806594","volume":"42","author":"AM Finch","year":"1999","unstructured":"Finch, A. M. et al. Low molecular weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42, 1965\u20131974 (1999).","journal-title":"J. Med. Chem."},{"key":"26387_CR12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1124\/mol.65.4.868","volume":"65","author":"DR March","year":"2004","unstructured":"March, D. R. et al. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol. Pharmacol. 65, 868\u2013879 (2004).","journal-title":"Mol. Pharmacol."},{"key":"26387_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep24575","volume":"6","author":"V Seow","year":"2016","unstructured":"Seow, V. et al. Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists. Sci Rep 6, 24575, https:\/\/doi.org\/10.1038\/srep24575 (2016).","journal-title":"Sci Rep"},{"key":"26387_CR14","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/sj.bjp.0702938","volume":"128","author":"NJ Paczkowski","year":"1999","unstructured":"Paczkowski, N. J. et al. Pharmacological characterization of antagonists of the C5a receptor. Br J Pharmacol 128, 1461\u20131466, https:\/\/doi.org\/10.1038\/sj.bjp.0702938 (1999).","journal-title":"Br J Pharmacol"},{"key":"26387_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1124\/jpet.105.086835","volume":"314","author":"TM Woodruff","year":"2005","unstructured":"Woodruff, T. M. et al. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 314, 811\u2013817 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"26387_CR16","doi-asserted-by":"publisher","first-page":"8727","DOI":"10.4049\/jimmunol.181.12.8727","volume":"181","author":"T Woodruff","year":"2008","unstructured":"Woodruff, T. et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J. Immunol. 181, 8727\u20138734 (2008).","journal-title":"J. Immunol."},{"key":"26387_CR17","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1089\/neu.2016.4701","volume":"34","author":"PJC Biggins","year":"2017","unstructured":"Biggins, P. J. C., Brennan, F. H., Taylor, S. M., Woodruff, T. M. & Ruitenberg, M. J. The Alternative Receptor for Complement Component 5a, C5aR2, Conveys Neuroprotection in Traumatic Spinal Cord Injury. J Neurotrauma 34, 2075\u20132085, https:\/\/doi.org\/10.1089\/neu.2016.4701 (2017).","journal-title":"J Neurotrauma"},{"key":"26387_CR18","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4049\/jimmunol.0901005","volume":"183","author":"M Fonseca","year":"2009","unstructured":"Fonseca, M. et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer\u2019s disease. J. Immunol. 183, 1375\u20131383 (2009).","journal-title":"J. Immunol."},{"key":"26387_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1471-4159.2010.06595.x","volume":"113","author":"R Ager","year":"2010","unstructured":"Ager, R. et al. Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer\u2019s disease. J. Neurochem. 113, 389\u2013401 (2010).","journal-title":"J. Neurochem."},{"key":"26387_CR20","first-page":"529","volume":"8","author":"J Kohl","year":"2006","unstructured":"Kohl, J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr. Opin. Mol. Ther. 8, 529\u2013538 (2006).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"26387_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ejps.2008.01.009","volume":"33","author":"M Morgan","year":"2008","unstructured":"Morgan, M. et al. Pharmacokinetics of a C5a receptor antagonist in the rat after different sites of enteral administration. Eur. J. Pharm. Sci. 33, 390\u2013398 (2008).","journal-title":"Eur. J. Pharm. Sci."},{"key":"26387_CR22","doi-asserted-by":"publisher","first-page":"6560","DOI":"10.4049\/jimmunol.164.12.6560","volume":"164","author":"AJ Strachan","year":"2000","unstructured":"Strachan, A. J., Woodruff, T. M., Haaima, G., Fairlie, D. P. & Taylor, S. M. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J. Immunol. 164, 6560\u20136565 (2000).","journal-title":"J. Immunol."},{"key":"26387_CR23","unstructured":"US Department of Health and Human Services, F. D. A., Center for Drug Evaluation and Research (CDER), Center forVeterinary Medicine (CVM). Guidance for Industry: Bioanalytical Method Validation, Available at https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070107.pdf (2001)."},{"key":"26387_CR24","unstructured":"Agency, E. M. Guideline on bioanalytical method validation, Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf (2011)."},{"key":"26387_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cei.12220","volume":"175","author":"G Li","year":"2014","unstructured":"Li, G. et al. Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage. Clinical & Exp. Immunol. 175, 285\u2013295 (2014).","journal-title":"Clinical & Exp. Immunol."},{"key":"26387_CR26","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1096\/fj.10-174284","volume":"25","author":"HD Manthey","year":"2011","unstructured":"Manthey, H. D. et al. Complement C5a inhibition reduces atherosclerosis in ApoE\u2212\/\u2212 mice. Faseb J. 25, 2447\u20132455 (2011).","journal-title":"Faseb J."},{"key":"26387_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-10-119","volume":"10","author":"JD Lee","year":"2013","unstructured":"Lee, J. D. et al. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 10, 119, https:\/\/doi.org\/10.1186\/1742-2094-10-119 (2013).","journal-title":"J Neuroinflammation"},{"key":"26387_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.nbd.2014.02.008","volume":"66","author":"L Li","year":"2014","unstructured":"Li, L. et al. Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice. Neurobiol. of disease 66, 74\u201382 (2014).","journal-title":"Neurobiol. of disease"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26387-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26387-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26387-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T05:37:23Z","timestamp":1671601043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26387-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["26387"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-26387-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,25]]},"assertion":[{"value":"18 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8101"}}